Holista Colltech Shifts Focus to Advanced Nano-Collagen Applications

Holista Colltech Limited ( (AU:HCT) ) has provided an announcement.

Holista Colltech Limited has announced a strategic shift in its ovine collagen business, including the closure of its Collie facility and plans to establish a new modular production model. The company is focusing on developing nano-collagen for advanced medical applications, such as wound healing and bio-ink for organ printing, and has partnered with Akrivis Health Care to enhance its nano-collagen capabilities. Holista is also working on securing intellectual property rights and expanding its market presence through a proposed license agreement with Regenerex Pharma Inc. for international markets.

More about Holista Colltech Limited

Holista Colltech Limited operates in the biomedical sector, focusing on four main business segments: ovine collagen, health supplements, food ingredients, and infection control/agriculture. The company leverages Australia’s high animal health standards to produce high-purity ovine collagen, which is more culturally and religiously accepted compared to mammalian collagen from cows and pigs.

Average Trading Volume: 289,470

Technical Sentiment Signal: Buy

Current Market Cap: A$14.29M

See more insights into HCT stock on TipRanks’ Stock Analysis page.